Literature DB >> 26653770

Cancer immunotherapy targeting neoantigens.

Yong-Chen Lu1, Paul F Robbins2.   

Abstract

Neoantigens are antigens encoded by tumor-specific mutated genes. Studies in the past few years have suggested a key role for neoantigens in cancer immunotherapy. Here we review the discoveries of neoantigens in the past two decades and the current advances in neoantigen identification. We also discuss the potential benefits and obstacles to the development of effective cancer immunotherapies targeting neoantigens. Published by Elsevier Ltd.

Entities:  

Keywords:  Cancer immunotherapy; Mutation; Neoantigen; Tumor immunology

Mesh：

Substances：

Year:  2015        PMID： 26653770      PMCID： PMC4862880          DOI： 10.1016/j.smim.2015.11.002

Source DB:  PubMed          Journal:  Semin Immunol        ISSN： 1044-5323            Impact factor:   11.130


  73 in total

Review 1.  Innate immune recognition.

Authors:  Charles A Janeway; Ruslan Medzhitov
Journal:  Annu Rev Immunol       Date:  2001-10-04       Impact factor: 28.527

2.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

3.  A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.

Authors:  P G Coulie; F Lehmann; B Lethé; J Herman; C Lurquin; M Andrawiss; T Boon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

4.  A point mutation in the NFYC gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human squamous cell lung carcinoma.

Authors:  Mitsuhiro Takenoyama; Jean-Françis Baurain; Manabu Yasuda; Tomoko So; Masakazu Sugaya; Takeshi Hanagiri; Kenji Sugio; Kosei Yasumoto; Thierry Boon; Pierre G Coulie
Journal:  Int J Cancer       Date:  2006-04-15       Impact factor: 7.396

5.  Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

Authors:  R F Wang; X Wang; A C Atwood; S L Topalian; S A Rosenberg
Journal:  Science       Date:  1999-05-21       Impact factor: 47.728

6.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

7.  Immunogenicity without immunoselection: a mutant but functional antioxidant enzyme retained in a human metastatic melanoma and targeted by CD8(+) T cells with a memory phenotype.

Authors:  Marialuisa Sensi; Gabriella Nicolini; Marina Zanon; Chiara Colombo; Alessandra Molla; Ilaria Bersani; Raffaella Lupetti; Giorgio Parmiani; Andrea Anichini
Journal:  Cancer Res       Date:  2005-01-15       Impact factor: 12.701

8.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.

Authors:  T Wölfel; M Hauer; J Schneider; M Serrano; C Wölfel; E Klehmann-Hieb; E De Plaen; T Hankeln; K H Meyer zum Büschenfelde; D Beach
Journal:  Science       Date:  1995-09-01       Impact factor: 47.728

9.  NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.

Authors:  Aaron P Rapoport; Edward A Stadtmauer; Gwendolyn K Binder-Scholl; Olga Goloubeva; Dan T Vogl; Simon F Lacey; Ashraf Z Badros; Alfred Garfall; Brendan Weiss; Jeffrey Finklestein; Irina Kulikovskaya; Sanjoy K Sinha; Shari Kronsberg; Minnal Gupta; Sarah Bond; Luca Melchiori; Joanna E Brewer; Alan D Bennett; Andrew B Gerry; Nicholas J Pumphrey; Daniel Williams; Helen K Tayton-Martin; Lilliam Ribeiro; Tom Holdich; Saul Yanovich; Nancy Hardy; Jean Yared; Naseem Kerr; Sunita Philip; Sandra Westphal; Don L Siegel; Bruce L Levine; Bent K Jakobsen; Michael Kalos; Carl H June
Journal:  Nat Med       Date:  2015-07-20       Impact factor: 53.440

10.  Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions.

Authors:  Yong-Chen Lu; Xin Yao; Jessica S Crystal; Yong F Li; Mona El-Gamil; Colin Gross; Lindy Davis; Mark E Dudley; James C Yang; Yardena Samuels; Steven A Rosenberg; Paul F Robbins
Journal:  Clin Cancer Res       Date:  2014-07-01       Impact factor: 12.531
View more
  97 in total

1.  Ex Vivo PD-L1/PD-1 Pathway Blockade Reverses Dysfunction of Circulating CEA-Specific T Cells in Pancreatic Cancer Patients.

Authors:  Yuan Chen; Shao-An Xue; Shahriar Behboudi; Goran H Mohammad; Stephen P Pereira; Emma C Morris
Journal:  Clin Cancer Res       Date:  2017-07-14       Impact factor: 12.531

2.  Melanoma vaccines: clinical status and immune endpoints.

Authors:  Deena M Maurer; Lisa H Butterfield; Lazar Vujanovic
Journal:  Melanoma Res       Date:  2019-04       Impact factor: 3.599

Review 3.  Genomics of adult and pediatric solid tumors.

Authors:  Zahraa Rahal; Farah Abdulhai; Humam Kadara; Raya Saab
Journal:  Am J Cancer Res       Date:  2018-08-01       Impact factor: 6.166

4.  IL17A Regulates Tumor Latency and Metastasis in Lung Adeno and Squamous SQ.2b and AD.1 Cancer.

Authors:  Ran You; Francesco J DeMayo; Jian Liu; Sung-Nam Cho; Bryan M Burt; Chad J Creighton; Roberto F Casal; Donald R Lazarus; Wen Lu; Hui-Ying Tung; Xiaoyi Yuan; Andrea Hill-McAlester; Myunghoo Kim; Sarah Perusich; Loraine Cornwell; Daniel Rosen; Li-Zhen Song; Silke Paust; Gretchen Diehl; David Corry; Farrah Kheradmand
Journal:  Cancer Immunol Res       Date:  2018-04-13       Impact factor: 11.151

Review 5.  Multifunctional nanoparticles for cancer immunotherapy.

Authors:  Tayebeh Saleh; Seyed Abbas Shojaosadati
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

6.  Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Authors:  Douglas B Johnson; Mellissa J Nixon; Yu Wang; Daniel Y Wang; Emily Castellanos; Monica V Estrada; Paula I Ericsson-Gonzalez; Candace H Cote; Roberto Salgado; Violeta Sanchez; Phillip T Dean; Susan R Opalenik; Daniel M Schreeder; David L Rimm; Ju Young Kim; Jennifer Bordeaux; Sherene Loi; Leora Horn; Melinda E Sanders; P Brent Ferrell; Yaomin Xu; Jeffrey A Sosman; Randall S Davis; Justin M Balko
Journal:  JCI Insight       Date:  2018-12-20

Review 7.  Targeting neoantigens to augment antitumour immunity.

Authors:  Mark Yarchoan; Burles A Johnson; Eric R Lutz; Daniel A Laheru; Elizabeth M Jaffee
Journal:  Nat Rev Cancer       Date:  2017-02-24       Impact factor: 60.716

Review 8.  The role of proteomics in the age of immunotherapies.

Authors:  Sarah A Hayes; Stephen Clarke; Nick Pavlakis; Viive M Howell
Journal:  Mamm Genome       Date:  2018-07-25       Impact factor: 2.957

9.  Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.

Authors:  Fangjun Chen; Zhengyun Zou; Juan Du; Shu Su; Jie Shao; Fanyan Meng; Ju Yang; Qiuping Xu; Naiqing Ding; Yang Yang; Qin Liu; Qin Wang; Zhichen Sun; Shujuan Zhou; Shiyao Du; Jia Wei; Baorui Liu
Journal:  J Clin Invest       Date:  2019-03-05       Impact factor: 14.808

Review 10.  Neoantigen-based cancer immunotherapy.

Authors:  Sara Bobisse; Periklis G Foukas; George Coukos; Alexandre Harari
Journal:  Ann Transl Med       Date:  2016-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.